Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer
Bioventus (Nasdaq: BVS) has appointed Dave Crawford as Vice President, Investor Relations and Treasurer, bringing over 20 years of finance experience to the role.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bioventus (Nasdaq: BVS) has appointed Dave Crawford as Vice President, Investor Relations and Treasurer, bringing over 20 years of finance experience to the role. Previously with Avanos Medical, Crawford has a strong background in finance and treasury from Kimberly-Clark and Eli Lilly. His MBA is from Duke University, and he holds a Bachelor’s in Accounting from Notre Dame. The company continues to focus on delivering clinically proven, cost-effective products for healing.
Positive
- Appointment of Dave Crawford strengthens investor relations and treasury management.
- Crawford's extensive experience in finance is a strategic asset for the company.
Negative
- None.
Details
News Market Reaction – BVS
The recorded move for BVS in the trading session of this news was -3.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. Crawford has more than 20 years of experience across multiple areas of finance and comes to Bioventus from Avanos Medical, Inc. where he served for nearly seven years as its Vice President Treasurer, Investor Relations and Financial Planning and Analysis.
“We are happy to welcome Dave to lead our investor relations department and manage treasury at Bioventus,” said Greg Anglum, Senior Vice President and CFO. “Dave’s record of accomplishments, strong relationships within the financial community and career in finance and treasury are a perfect fit for the Company.”
Previously, Crawford spent several years in finance and treasury roles with Kimberly-Clark Corporation and was later promoted to Chief Financial Officer of the company’s Global Healthcare Division. Prior to that, Crawford held financial and treasury roles with Eli Lilly & Company. He began his career as a tax consultant with Arthur Andersen.
Crawford has an MBA from Duke University and received a Bachelor of Business Administration in Accounting from the University of Notre Dame.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter.
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Media Contact:
Thomas Hill
Bioventus
919-474-6715
thomas.hill@bioventus.com
Investor Inquiries:
Mike Piccinino, CFA, IRC
Westwicke/ICR
investor.relations@bioventus.com
